AU2021263136A1 - Materials and methods for treating juvenile idiopathic arthritis - Google Patents

Materials and methods for treating juvenile idiopathic arthritis Download PDF

Info

Publication number
AU2021263136A1
AU2021263136A1 AU2021263136A AU2021263136A AU2021263136A1 AU 2021263136 A1 AU2021263136 A1 AU 2021263136A1 AU 2021263136 A AU2021263136 A AU 2021263136A AU 2021263136 A AU2021263136 A AU 2021263136A AU 2021263136 A1 AU2021263136 A1 AU 2021263136A1
Authority
AU
Australia
Prior art keywords
tnf
antibody
jia
amino acid
pediatric patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021263136A
Other languages
English (en)
Inventor
Karen BENSLEY
Michael Clark
Jocelyn LEU
Zhenhua Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority claimed from PCT/IB2021/053429 external-priority patent/WO2021220140A1/en
Publication of AU2021263136A1 publication Critical patent/AU2021263136A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Farming Of Fish And Shellfish (AREA)
AU2021263136A 2020-04-27 2021-04-26 Materials and methods for treating juvenile idiopathic arthritis Pending AU2021263136A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063015902P 2020-04-27 2020-04-27
US202063015889P 2020-04-27 2020-04-27
US202063015894P 2020-04-27 2020-04-27
US63/015,902 2020-04-27
US63/015,894 2020-04-27
US63/015,889 2020-04-27
PCT/IB2021/053429 WO2021220140A1 (en) 2020-04-27 2021-04-26 Materials and methods for treating juvenile idiopathic arthritis

Publications (1)

Publication Number Publication Date
AU2021263136A1 true AU2021263136A1 (en) 2023-01-05

Family

ID=78336251

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021263136A Pending AU2021263136A1 (en) 2020-04-27 2021-04-26 Materials and methods for treating juvenile idiopathic arthritis

Country Status (9)

Country Link
EP (1) EP4143226A4 (https=)
JP (1) JP2023524668A (https=)
KR (1) KR20230005284A (https=)
CN (1) CN115461365A (https=)
AU (1) AU2021263136A1 (https=)
BR (1) BR112022021766A2 (https=)
CA (1) CA3127807A1 (https=)
IL (1) IL297623A (https=)
MX (1) MX2022013502A (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961746B (zh) * 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
US10465003B2 (en) * 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
KR20190113858A (ko) * 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법

Also Published As

Publication number Publication date
EP4143226A1 (en) 2023-03-08
EP4143226A4 (en) 2024-05-29
CN115461365A (zh) 2022-12-09
MX2022013502A (es) 2023-02-01
CA3127807A1 (en) 2021-10-27
KR20230005284A (ko) 2023-01-09
IL297623A (en) 2022-12-01
JP2023524668A (ja) 2023-06-13
BR112022021766A2 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
US12291566B2 (en) Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
US20220324959A1 (en) Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
EP3976648A1 (en) Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
US20210340245A1 (en) Materials and Methods for Treating Juvenile Idiopathic Arthritis
JP7689074B2 (ja) 若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
US20220195028A1 (en) Anti-TNF Antibodies, Compositions, and Methods for the Treatment of Active Ankylosing Spondylitis
AU2021263136A1 (en) Materials and methods for treating juvenile idiopathic arthritis
US20220064278A1 (en) Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
EA052133B1 (ru) Материалы и способы лечения ювенильного идопатического артрита
EA047762B1 (ru) Композиции антитела к фно и способы лечения ювенильного идиопатического артрита